2019
HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy
Rottmann D, Snir OL, Wu X, Wong S, Hui P, Santin AD, Buza N. HER2 testing of gynecologic carcinosarcomas: tumor stratification for potential targeted therapy. Modern Pathology 2019, 33: 118-127. PMID: 31477811, DOI: 10.1038/s41379-019-0358-x.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2-positive tumorsSerous carcinomaSarcoma componentHER2 statusGynecologic carcinosarcomaHER2 expression/amplificationRecent phase II clinical trialPhase II clinical trialCarboplatin-paclitaxel chemotherapyEquivocal HER2 expressionProgression-free survivalAppropriate patient selectionExpression/amplificationFemale genital tractMembranous staining patternHER2 protein expressionHER2 immunohistochemical scoresUterine primaryDismal prognosisPatient selectionCarcinoma componentMixed carcinomasHER2 expressionClinical trials
2018
Novel targeted therapies in ovarian and uterine carcinosarcomas.
Han C, Altwerger G, Menderes G, Haines K, Feinberg J, Lopez S, Manzano A, Varughese J, Santin AD. Novel targeted therapies in ovarian and uterine carcinosarcomas. Discovery Medicine 2018, 25: 309-319. PMID: 30021104.Peer-Reviewed Original ResearchConceptsMultiple genes/pathwaysPI3K/Akt/mTORFemale genital tractEffective treatment strategiesUnmet medical needAkt/mTORGynecologic tumorsPoor prognosisUterine carcinosarcomaAggressive tumorsTreatment modalitiesBiphasic tumorWhole-exome sequencing studiesGenital tractTreatment strategiesCarcinomatous componentCarcinosarcomaMedical needAberrant activationTumorsGenes/pathwaysCell cycle regulationGenetic landscapeSequencing studiesPrognosis
2004
Current treatment options for endometrial cancer
Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCell DifferentiationCisplatinDoxorubicinEndometrial NeoplasmsFemaleHumansHysterectomyNeoplasm InvasivenessNeoplasm Recurrence, LocalOvariectomyPaclitaxelPrognosisRadiotherapy, AdjuvantReceptor, ErbB-2Risk FactorsSurvival AnalysisTrastuzumabConceptsEndometrial cancerMyometrial invasionStage I endometrial cancer patientsLow-toxicity regimenEndometrial cancer patientsLymph node dissectionRecurrent endometrial cancerTotal abdominal hysterectomyClear cell histologyCornerstone of treatmentPostoperative radiation therapyImportant prognostic factorCurrent treatment optionsCombination of cisplatinFemale genital tractAttractive therapeutic strategyMajority of casesType II receptorExtrapelvic recurrenceAbdominal hysterectomyNode dissectionPelvic radiotherapyPelvic recurrenceSystemic chemotherapyVaginal bleeding